NATCO Pharma Limited announces the launch of additional strengths for the generic version of Revlimid (lenalidomide capsules), in 2.5 mg, and 20 mg strengths, in the United States, via an exchange filing.
The launch is through its marketing partner Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd.
With this launch the companies made available all the strengths of lenalidomide in the US market.
Lenalidomide capsules are a prescription medicine used in adults for the treatment of multiple myeloma.
Kirloskar Ferrous Industries Will Invest ₹3,000 Crore In Hiriyuru Plant In Karnataka
State Bank Of India Embarks On Drive To Cut The KYC Process To A Single One Across Branches
Kentucky Plane Crash Video: Exact Moments Of Impact Captured As UPS Cargo Plane Explodes In Louisville; 3 Killed
Market Outlook: Technical Call Of The Day & Top 5 Stocks In Focus For November 6, 2025
